2019, the year that got serialization done!
The past 12 months have been busy as many companies fought to comply with serialization regulations.
Brexit may have dominated the headlines throughout 2019, but for many contract organizations, the past 12 months have been defined by other issues. Allan Bowyer, Director of Industry Marketing, TraceLink, shares what he believes have been the trends or innovations that have been the most influential in the industry.
"It is impossible to talk about 2019 without mentioning the serialization regulations that have forced significant developments and opened the door for further innovation in the management of the pharma supply chain.
"The EU Falsified Medicines Directive (FMD) came into force in February and its rollout wasn’t a simple ‘find solution-implement-comply’ transition. A number of countries implemented post-deadline stabilization periods to help ease the transition and prevent medicine shortages – and with good reason. The success of FMD depends on pharmacists being able to scan and verify every serialized product, but a significant number of dispensers in Europe are still non-compliant, with France and the UK among those having the highest rates of missed connectivity. Broadly speaking, regulators in each country gave dispensers leeway to dispense packs where they were confident an alert was false. Some country authorities have now ended their stabilization periods, while others are beginning to wind down with most expecting full compliance by February 2020.
"Data integrity issues have also thrown out some notable challenges in various ways throughout the year. When solutions first went live, handling falsified medicine alerts was a significant concern for manufacturers and dispensers, with users saying they had not anticipated having to deal with so many alerts so soon. Fortunately, most of these were caused by data entry problems rather than intentional wrongdoing - this has been somewhat resolved over time, but these alert causes are still much higher than expected.
"There has also been a notable increase in the number of false alerts occurring due to errors made by dispensers, mostly caused by misconfigured scanners and double scanning/decommissioning. These are still false alerts and the EMVO has tasked manufacturers with identifying the root causes of alerts and working to reduce the alert rate from its current rate (latest according to EMVO is 2.87%) to less than 0.05%. This will be an ongoing effort likely to carry on for months to come."
Russia
"We saw a huge uplift in engagement from current customers in Russia, as well as a number of new partners that operate in the region in mid-2019.
"The serialization and reporting requirements for Russia are considered the most complex in the world. As of 1 January 2020, all medicine imported into and traded within Russia must comply, and this applies to more than 370 manufacturers.
"The shortness of the deadline and lateness of clarifications when it came to the requirements of the law and technical guidelines (which continue to evolve), combined with the incredible complexity, has put serious pressure on businesses operating in the country, and some, though late to the game, have not yet started implementation. For those that haven’t, it is imperative to choose a compliance solution, start implementing it now and start training personnel on the new system and business processes as soon as possible after that."
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance